TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women over the age of 18 who will undergo the placement of a sub-urethral sling for the treatment of stress urinary incontinence~Exclusion Criteria:~* Exclusion criteria are those with a known allergy to macrobid, those with glucose-6-phosphate deficiency, renal impairment, women breast feeding or with a known pregnancy, patients taking medications for gout, and those with known risk factors for complicated UTI (polycystic renal disease, nephrolithiasis, neurogenic bladder, diabetes, immuno-suppression, etc).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
- Placebo (Type: PLACEBO_COMPARATOR): Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Timing of Dinoprostone Administration Prior to Office Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous patients who have an indication for office hysteroscopy~Exclusion Criteria:~* Parous patients, menopausal patients and patients with cervical pathology, and previous cervical surgery will be excluded from the study. Moreover, patients with severe vaginal bleeding, allergy to dinoprostone

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- long interval dinoprostone (Type: EXPERIMENTAL): A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
- short interval dinoprostone (Type: ACTIVE_COMPARATOR): A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablets(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for Attention Deficit Hyperactivity Disorder (ADHD) and are considered to require medication therapy~* Participants that agreed to observe visit schedules and willingly complete the evaluation defined by participant (possibly to be completed by parents/guardians) during the treatment period~* Participants and parents/guardians that are able to understand the participation procedures of the research and spontaneously request the discontinuation therein at any time~* Participants that offered spontaneous consent for participation~* Participants whose guardian/legal representative provided spontaneous written consent~Exclusion Criteria:~* Hypersensitivity to methylphenidate HCl~* Participants diagnosed with major depression or anxiety disorders according to DSM-IV Diagnostic criteria and who requires drug therapy~* Participants with a history of bipolar disorder, psychotic disorder, and substance abuse disorder ordiagnosed with an overall developmental disorder, organic brain disorder, seizure (sudden, uncontrolled muscle spasms and loss of consciousness resulting from abnormal brain function) disorder, movement disorder requiring the medication therapy, or with a family history of Tourette's syndrome (a neuropsychological disorder that causes marked distress or significant impairment in social, occupational, or other important areas of functioning)~* Taken Osmotic Release Oral System (OROS) Methylphenidate within 3 months prior to screening~* Currently taking alpha-2 adrenergic receptor agonist, antidepressant, antipsychotic, benzodiazepines, modafinil, anticonvulsant (drug used to stop seizures) or health food supplements that may have a central nervous system activity

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- OROS Methylphenidate HCl (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, aged 18 years and above~2. A clinical diagnosis of major depressive disorder (MDD)~3. Is being treated with one of the following SSRI or SNRI antidepressants as monotherapy:~   * Citalopram~  * Escitalopram~  * Paroxetine~  * Fluoxetine~  * Sertraline~  * Duloxetine~  * Venlafaxine~  * Desvenlafaxine~  * Venlafaxine XR~4. Has a history of inadequate response to antidepressant treatments~Exclusion Criteria:~1. Patient has a psychotic disorder other than MDD~2. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program~3. Patient has a history or symptoms of long QT syndrome~Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pimavanserin 34 mg + SSRI/SNRI (Type: EXPERIMENTAL): Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
- Placebo + SSRI/SNRI (Type: PLACEBO_COMPARATOR): Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase2a Primaquine Dose Escalation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age \>= 18 years and \< 50 years~* Malaria blood thick film positive~* Presence of gametocytes on thick blood film~* Agrees to admission to study ward for 26 hours post diagnosis and available for follow up visits~* No allergies to study drugs~* Hemoglobin \>= 8 g/dl~* No evidence of severe or chronic disease~* Written, informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- dihydroartemisinin-piperaquine only (Type: ACTIVE_COMPARATOR): dihydroartemisinin -piperaquine (DP) only
- DP and 0.125 mg/kg primaquine (Type: EXPERIMENTAL): DP and single dose oral 0.125 mg/kg primaquine
- DP and 0.5 mg/kg primaquine (Type: EXPERIMENTAL): DP and single dose oral 0.5 mg/kg primaquine
- DP and 0.25 mg/kg primaquine (Type: EXPERIMENTAL): DP and a single dose oral 0.25 mg/kg primaquine
- DP and 0.0625 mg/kg primaquine (Type: EXPERIMENTAL): DP and a single dose oral 0.0625 mg/kg primaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective unilateral total knee replacement for primary osteoarthritis of knee~* ASA (American Society of Anesthesiologists) grading 1 or 2~Exclusion Criteria:~* Rheumatoid arthritis or seronegative arthritis~* Allergy to any medications used in the standard protocol (Methylprednisolone, adrenaline, ropivacaine, ketorolac, bupivacaine, ketorolac, pepcidine, transamin, gabapentin, voltaren, panadol, DF118)~* Chronic opioid use~* Substance dependence~* Patients attending chronic pain clinic~* Psychiatric or neurological condition that may influence pain perception or reporting~* Chronic illness that preclude the use of the medications in the standard protocol~* Hepatitis B carrier or Elevated bilirubin or ALT~* Active peptic ulcer disease~* Uncontrolled diabetic patients with HbA1c \>7% in recent 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone Group (Type: EXPERIMENTAL): The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
- Placebo Group (Type: PLACEBO_COMPARATOR): The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with evidence of chronic HCV (all genotypes) documented pretransplantation~* HCV RNA ≥ 10,000 IU/mL at screening~* Absence of organ rejection as documented by post transplant liver biopsy taken no more than 12 months prior to baseline/Day 1 visit~* Liver transplant ≥ 6 months and ≤ 12 years prior to screening~* Naive to all nucleotide/nucleoside treatments for chronic HCV infection~Exclusion Criteria:~* Multiorgan transplant that includes heart or lung recipient~* Subjects with de novo or recurrent Hepatocellular Carcinoma(HCC) post transplant~* Current use of corticosteroids at any dose \> 5mg of prednisone/day (or equivalent dose of corticosteroid)~* Infection with hepatitis B virus (HBV) or HIV at screening~* Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV (Type: EXPERIMENTAL): Participants will receive sofosbuvir+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluoride Varnish Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion~* Children \< 44 months old~* Caries-free~* 4 erupted maxillary incisors~* Residing in fluoridated community (San Francisco)~Exclusion~* Cleft Palate~* Developmental or learning disabilities~* Children with transient residence (homeless, migrant, foster home)~* Children with an another household member participating in the study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- Counseling Only (Type: NO_INTERVENTION): Counseling Only
- FV every 12mo for 24mo + Counsel (Type: EXPERIMENTAL): Preventive fluoride varnish every 12mo for 24mo plus Counseling
- FV every 6mo for 24mo + Counseling (Type: EXPERIMENTAL): Preventive fluoride varnish every 6mo for 24mo plus Counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter \[cm\]):~  1. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with the same score on both sides of the face; and~ 2. A minimum of 20 inflammatory lesions (papules and pustules) in total with at least 10 on each side; and~ 3. No more than 2 nodules (greater than or equal to \[\>=\] 1 cm in diameter) on the face; and~ 4. A minimum of 10 atrophic acne scars in total (\>2 mm)~* Participant with a symmetrical number of the following lesions/scars on the whole face:~  1. Inflammatory and non-inflammatory lesions; and~ 2. Atrophic acne scars (minimum of 4 scars per half-face)~* The participant is a female of non-childbearing potential~* If a female of childbearing, potential uses oral contraceptives that are also approve for treating acne vulgaris~* Other protocol defined inclusion criteria could apply~Key Exclusion Criteria:~* Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne and acne requiring systemic treatment~* Participant with any acne cyst on the face or with more than 3 excoriated acne lesions~* Participant with known active or chronic allergies or suspected allergy to trifarotene or excipients of the formulation~* Participant with facial dermal conditions (for example, tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator~* Participant with known impaired hepatic or renal functions, based on medical history

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Trifarotene Vehicle Cream (Type: PLACEBO_COMPARATOR): None
- Trifarotene (CD5789) 50 mcg/g Cream (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Subjective Sleep Study of a Prototype Nasal Dilator

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with leptorrhine noses~* Subjects suffering from chronic nocturnal nasal congestion and report trouble with sleep

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prototype Nasal Dilator (Type: EXPERIMENTAL): Prototype Nasal Dilator
- Marketed Nasal Strip (Type: ACTIVE_COMPARATOR): Marketed Nasal Strip
- Placebo Nasal Strip (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have completed through Week 41 visit in the TKT025 study.~* Patients must have voluntarily signed an IRB/EC approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.~* Patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator.~* Female and male patients of child bearing potential must agree to use a medically acceptable method of contraception at all times during the study. Female patients must have a negative serum pregnancy test on enrollment.~Exclusion Criteria:~* Patient has received treatment with non-Gaucher disease related investigational drug or device within the past 30 days prior to study entry; such use during the study is not permitted.~* Patient has a clinically relevant medical condition (e.g., HIV, hepatitis B or C) that would make implementation of the protocol difficult and/or confound an assessment of the effects of the experimental therapy and its adverse events.~* Patient, patient's parent(s), or patient's legal guardian is unable to understand the nature, scope and possible consequences of the study.~* Patient is unable to comply with the protocol, e.g. uncooperative attitude, medical condition, inability to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GA-GCB (Type: EXPERIMENTAL): 15-60 U/kg every other week via intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque Ps based on a confirmed diagnosis of chronic Ps vulgaris for at least 6 months prior to baseline.~* Have ≥10% BSA involvement at screening and baseline.~* Have both an sPGA score ≥3 and PASI score ≥12 at screening and baseline.~* Are candidates for phototherapy and/or systemic therapy.~Exclusion Criteria:~* Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline.~* Drug-induced psoriasis.~* Ongoing use of prohibited treatments.~* Have previously completed or withdrawn from this study, or have previously exposed to ixekizumab or any other biologic drug directly targeting interleukin-17 (IL-17) (such as secukinumab) or the IL-17 receptor.~* Have concurrent or recent use of any biologic agent within washout periods or \<5 half-lives prior to baseline, whichever is longer.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab 80mg Q4W (Type: EXPERIMENTAL): Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
- Ixekizumab 80mg Q2W (Type: EXPERIMENTAL): Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete